MedTrace Logo

Phase I Study GX-G3 in Healthy Subjects

NCT01951027 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2015-01-29

No results posted yet for this study

Summary

pharmacokinetics/pharmacodynamics of GX-G3 after single subcutaneous administration in healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

GX-G3 12.5 μg/kg or Placebo

Single SC injection

DRUG

GX-G3 25 μg/kg or Placebo

Single SC injection

DRUG

GX-G3 50 μg/kg or Placebo

Single SC injection

DRUG

GX-G3 100 μg/kg or Placebo

Single SC injection

Sponsors & Collaborators

  • Genexine, Inc.

    lead INDUSTRY

Principal Investigators

  • Sang-In Yang, Ph.D · Genexine, Inc, Clinical development Department

  • Jae Woo Kim, M.D. · CHUNGNAM NATIONAL UNIVERSITY HOSPITAL Clinical Research Center

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-07-31
Completion
2014-12-31

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01951027 on ClinicalTrials.gov